anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Restenosis is a major limitation of percutaneous coronary intervention. Migration and proliferation of vascular cells remain a cornerstone in neointimal formation and vascular healing. Recently, we have shown that local delivery of 17-beta-estradiol (17.beta.E) prevents restenosis following angioplasty by improving vascular healing. Indeed, 17.beta.E inhibited muscle cell proliferation but, on the contrary, favorized the endothelial cell proliferation and function. We herein investigate the effect of an acute administration of 17.beta.E on mitogen-activated protein kinase (MAPK) activity, migration and proliferation of porcine aortic endothelial cells (PAEC) and smooth muscle cells (PSMC). On cultured PAEC and PSMC, we evaluated the effect of 17.beta.E (10 -10 to 10 -7 M) ~ selective 17.beta.E antagonists (Tamoxifen (Tam), 4OH-Tamoxifen (4OH-Tam) and Raloxifen (Ral)) on cell migration and proliferation. The results suggest that in PSMC, chemotatic and mitogenic effect of PDGF-BB as well as p38 and p42/44 MAPK phosphorylation are inhibited by 17.beta.E. In contrast, 17.beta.E promotes in PAEC the phosphorylation of p42/44 and p38 MAPK as well as the migration and proliferation of these cells. The effects of 17.beta.E  are reversed by the antagonists on these markers in both cell types. In conclusion, 17.beta.E may improve the vascular healing process by promoting PAEC proliferation and migration and by inhibiting the same events in PSMC. Since at least two estrogen receptors are (ER .alpha. and ER .beta.) are involved in estrogens activity, we propose to silence with antisense molecules the expression of one or both receptors, alone or in combination with the administration of 17.beta.E, to optimize the effect of estrogens on vascular target cells, as well as on other estrogen-responsive cells.
Chemotherapeutic agents are used to treat infections caused by bacteria, virus, protozoa, parasites, and various malignant diseases like cancer. The major problem associated with use of chemotherapeutic agents is resistance to chemotherapeutic agents. Mechanisms underlying resistance to chemotherapeutic agents include inactivation/modification of antibiotic (beta-lactams, chloramphenicol), insensitive target site (beta-lactams, glycopeptides, macrolides, tetracyclines), decreased drug accumulation in the form of enhanced efflux (tetracyclines, chloroquine, macrolides, anticancer drugs), by-pass of antibiotic sensitive step (methicillin, sulphonamides) etc. The common mechanisms underlying drug resistance is to restrict concentration of drug at the site of action usually intracellular. This can be in the form or restricting the entry of the drug into the cell by various mechanisms including altered cell wall permeability. It can also be in the form of removing the drug from site of action e.g. intracellular so that therapeutic concentration are not achieved. The drugs restoring sensitivity of chemotherapeutic agents are broadly known as chemosensitizers. Compounds belonging to a group of R-1-3-benzodiaxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to a group of R-1-3-benzodiaxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to R-1-3 benzodiaxole group. It is found to reverse resistance to chemotherapeutic agents like rifampicin at dose which is easily achievable after oral ingestion of the drug.
NEW MATERIAL:Isocholesterol alkyleneoxide addition compound of formula (R<1> is steroid skeleton of isocholesterol; R<2> is H or CH<3>; n is 5-100). EXAMPLE:Isocholesterol propyleneoxide addition compound. USE:Cosmetic base having lower melting point than isochlesterol, and desirable handleability. An emulsifying agent or a solubilizing agent having cell activating activity for cream, milky lotion, lipstick, hair tonic, etc. Also useful as an ointment base, cleansing cream, etc. PROCESS:The compound of the formula is prepared by reacting isocholesterol with an alkyleneoxide, if necessary in the presence of a catalyst such as KOH, at 100- 200 deg.C.
The study involves 1 screening visit of approximately 1 hour and 9 study days of approximately 8 hours. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, habitual dietary intake, physical activity level (PASE), and quality of life (SGRQ-C) will be assessed.

To test the relation between plasma amino acid, triglycerides, and glucose concentration measured by standard methods (such as finger stick) and continuous wearable devices, a premarket FDA-approved continuous glucose monitor (CGM) from Abbott (FreeStyle Libre Pro) that monitors glucose concentrations every 15 min is used. The single-use sensors are placed on the upper arm and contain a very tiny 5 mm filament (\<0.4 mm diameter) that is introduced into the skin when the sensor is placed. On the first study day, the CGM will be placed to monitor glucose concentrations until the last study day. At least every 14 days, sensors will be replaced by new ones. On each study day, body weight and height will be measured and the glucose concentration data will be downloaded from the sensor onto the reader device. A catheter will be inserted in a peripheral vein of the lower arm or hand to enable blood sampling. The arm will be put in a hot box to allow collecting arterialized venous blood samples. After taking a baseline blood sample, the predefined meal will be consumed within 10 min. Small arterialized venous blood samples (5 ml) will subsequently be drawn at times: 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, and 480 minutes (13 blood samples, total blood approx 65 ml). Samples will be collected in predefined tubes, plasma/serum separated, aliquoted, and stored at -80 deg. Celsius for later assays and/or send to a local accredited laboratory for the concentrations of amino acids and other parameters (including fatty acids, glucose, insulin).
Impaired gait is prevalent and raises the fall risk in people with Parkinson's Disease (PwPD). Gait speed, step length, and cadence are three interrelated components of human gait, as speed is determined by step length and cadence. Auditory cues, such as metronomes, have been shown to aid training for PwPD. The purpose of this study is to examine if controlling cadence and speed improves overground gait parameters in PwPD better than only controlling speed. Two groups of PwPD will participate. Both groups will attend a single treadmill training session. Both groups will complete overground walking trials as a pre-test measurement. One group will receive treadmill training in which cadence, via a metronome, and speed are controlled, while only speed is controlled for the other group. Both groups will complete the same overground walking trials as a post-test measurements. The specific aim of this study is to determine the effects of metronome cues and gait speed versus gait speed alone treadmill training on spatiotemporal gait parameters when walking overground in PwPD.
The prediction of protein function as well as the reconstruction of evolutionary genesis employing sequence comparison at large is still the most powerful tool in sequence analysis. Due to the exponential growth of the number of known protein sequences and the subsequent quadratic growth of the similarity matrix, the computation of the Similarity Matrix of Proteins (SIMAP) becomes a computational intensive task. The SIMAP database provides a comprehensive and up-to-date pre-calculation of the protein sequence similarity matrix, sequence-based features and sequence clusters. As of September 2009, SIMAP covers 48 million proteins and more than 23 million non-redundant sequences. Novel features of SIMAP include the expansion of the sequence space by including databases such as ENSEMBL as well as the integration of metagenomes based on their consistent processing and annotation. Furthermore, protein function predictions by Blast2GO are pre-calculated for all sequences in SIMAP and the data access and query functions have been improved. SIMAP assists biologists to query the up-to-date sequence space systematically and facilitates large-scale downstream projects in computational biology. Access to SIMAP is freely provided through the web portal for individuals (http://mips.gsf.de/simap/) and for programmatic access through DAS (http://webclu.bio.wzw.tum.de/das/) and Web-Service (http://mips.gsf.de/webservices/services/SimapService2.0?wsd1).
Chronic kidney disease (CKD) is characterized by persistent kidney dysfunction, ultimately resulting in end-stage renal disease (ESRD). Renal fibrosis is a crucial pathological feature of CKD and ESRD. However, there is no effective treatment for this condition. Despite the complex molecular mechanisms involved in renal fibrosis, increasing evidence highlights the crucial role of histone modification in its regulation. The reversibility of histone modifications offers promising avenues for therapeutic strategies to block or reverse renal fibrosis. Therefore, a comprehensive understanding of the regulatory implications of histone modifications in fibrosis may provide novel insights into more effective and safer therapeutic approaches. This review highlights the regulatory mechanisms and recent advances in histone modifications in renal fibrosis, particularly histone methylation and histone acetylation. The aim is to explore the potential of histone modifications as targets for treating renal fibrosis.
Start dose at 20 mg po od. If no clinical improvement(\<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
PURPOSE: To describe a severe case of crystalline retinopathy secondary to hyperoxaluria from short gut syndrome.
METHODS: Case report.
RESULTS: A 62-year-old Caucasian woman with short gut syndrome and end-stage renal disease from renal oxalosis presented with chronic bilateral vision loss. She had previously been treated for presumed occlusive vasculitis. Visual acuity on initial examination was 20/400 right eye and 20/100 left eye with an afferent pupillary defect of the right eye. Examination revealed attenuated retinal vasculature and diffuse crystalline infiltration of retinal arterial lumina and throughout the retinas bilaterally. Optical coherence tomography revealed inner retinal atrophy with crystalline deposition in the inner retinal layers. Fluorescein angiography demonstrated delayed vascular filling and dropout consistent with severe ischemic vasculopathy. It was concluded that the short-gut syndrome led to overabsorption of oxalate with subsequent hyperoxaluria leading to retinal atherosclerotic oxalosis.
CONCLUSION: Retinal calcium oxalate deposits due to hyperoxaluria have been previously noted; however, this degree of severe retinal vascular infiltration has not been described. Our patient was receiving hemodialysis, which is associated with high rebound increases in systemic oxalate concentrations. It is important to keep hyperoxaluria in mind as a potential cause of retinopathy in patients with end-stage renal disease presenting with vision loss.
A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross- linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart.
The invention relates to a traditional Chinese medicine preparation for treating rheumatism and internal lesion caused by overexertion, which is prepared from 45 active pharmaceutical ingredients, including angelica, red paeonia, roasted frankincense, roasted myrrh, safflower and the like. The preparation can be capsules, tablets, pills, powder or medicinal wine. The preparation method comprises the following steps: extracting the active pharmaceutical ingredients with water, preparing thick paste, drying, pulverizing to obtain water extraction medicinal powder, and preparing the water extraction medicinal powder into various preparation formulations; or pulverizing the active pharmaceutical ingredients to obtain raw medicinal powder, and preparing the raw medicinal powder into various preparation formulations; or putting the active pharmaceutical ingredients into a container, adding grain wine, soaking, filtering, and removing medicinal dregs to obtain the medicinal wine. The active pharmaceutical ingredients are organically combined according to the principle of 'monarch, minister, assistant and guide' to have synergistic action, so that the traditional Chinese medicine preparation has favorable curative effect on rheumatism and internal lesion caused by overexertion, and can treat both the symptoms and root causes. The traditional Chinese medicine preparation has obvious curative effect for treating limb arthralgia, rheumatoid arthritis, chronic infectious arthritis, gouty arthritis, lumbar vertebral disc pathological changes, scapulohumeral periarthritis, cervical pathological changes and the like. The traditional Chinese medicine preparation is prepared from pure traditional Chinese medicines, is convenient to use, has high safety and reliability, has no toxic or side effect on the liver, kidney, lung, stomach and spleen, and can be used for a long time.
Single center, non-randomized, open label, dose escalation Phase 1study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant produced by the Infectious Disease Research Institute (IDRI). This is a first-in-human study of FMP012. Thirty subjects, divided into 3 groups (10 subjects per group), will receive 3 doses of the FMP012/GLA-SE vaccine. Group 1 will receive 10 µg of FMP012 formulated with 2 µg GLA-SE adjuvant and Group 2 will receive 10 µg of FMP012 formulated with 5 µg GLA-SE adjuvant. Group 3 will receive 50 µg of FMP012 formulated with either 5 µg GLA-SE adjuvant (Group 3a) or 2 µg GLA-SE adjuvant (Group 3b). Determination of whether to proceed with Group 3a or Group 3b will be made by the principal investigator (PI) and the independent medical monitor after the second vaccination dose in Group 2 has been completed, based on predefined safety and group hold criteria in this protocol. There will be a staggered start for Group 1 and Group 2 separated by a minimum of 14 days. Group 3a or Group 3b will start vaccinations 2 weeks after the second vaccination for Group 2. The first and second vaccination doses in each group will be separated by 28 days and all groups will receive the third vaccination dose on the same day. The second and third vaccination doses in Group 1 will be separated by 84 days, Group 2 by 70 days, and Group 3 by 28 days. Six non-immunized infectivity control subjects will be enrolled prior to the challenge phase. All subjects from the Vaccination Group and Infectivity Control Group will participate in the primary malaria sporozoite challenge and will be required to stay at a hotel for evaluation for a maximum of 10 nights starting 9 days after the challenge. A directly monitored, sequentially allocated, open-label oral regimen of chloroquine or artemether/lumefantrine will be administered to all parasitemic subjects.
Background and Aim: The objectives of this study are to examine the effects of ethnicity, gender, and proton pump inhibitor (PPI, omeprazole), on the human gut microbiome. PPIs are commonly used for the treatment of acid-related disorders. The investigators hypothesize that PPI therapy might perturb microbial communities and alter the gut microbiome.

Methods: Healthy subjects of Chinese (n=12), Malay (n=12) and Indian (n=10) ancestry, aged 21-37 years old, were enrolled. They were required to provide a baseline stool sample (Day 1) and were then given a course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days. Stool samples were collected again on Day 7 and Day 14 (one week after stopping omeprazole). Microbial DNA was extracted from the stool samples. This was followed by PCR, library construction, 16S rRNA sequencing using Illumina MiSEQ, and statistical and bioinformatics analyses.
1. Technical Result Improvement of medicinal properties of the compound. 2. Essence The novel polymorph V of torasemide is characterized by physical-chemical properties disclosed in the description; it is used as a raw material for the preparation of crystalline modifications I and III of torasemide, amorphous torasemide modifications and pharmaceutically acceptable salts of torasemide, both as the active ingredient and as a diuretic and for treatment of other diseases, such as thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema; method for its production and pharmaceutical compositions containing the same. 3. Field of Application Medicine. Tables: 1
A method of making a hydrogel having antimicrobial properties. The hydrogel includes a hydrogel-forming polymer and an anti-microbial agent. The method includes mixing a hydrogel-forming polymer, such as a hydrophilic polymer, with water and cross-linking the polymer and water using an energy source. The method does not require any chemical additive to affect the cross-linking. The anti-microbial agent may be mixed with the hydrogel-forming polymer and water prior to cross-linking. Alternatively, the anti-microbial agent may be applied to a substrate onto which the hydrogel is placed such that the anti-microbial agent or the properties of the agent, or both, migrate into the hydrogel. The substrate may be a liner onto which the hydrogel is placed, a scrim located on or in the hydrogel, or other appropriate device.
Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including NAPRELAN®. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with NAPRELAN®. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), NAPRELAN® should be discontinued.
All children enrolled in the study will already receiving therapy. Each BT-child pair will have worked together regularly for at least 3 months prior to the study.
Hemifacial spasm is an uncontrollable, recurrent facial muscular contraction that typically occurs on one side of the face, cannot be suppressed, and can last the entire day and during sleep. The most common underlying cause of facial nerve compression is an enlarged or abnormal tracking blood vessel at the brainstem level. Clinical diagnoses are frequently based on a patient's medical history and physical examination. Before deciding on a course of action, however, an electromyogram and MRI are performed to determine the underlying cause. Due to its high effectiveness (success rates of 85% to 95%) and low frequency of adverse reactions, botulinum toxin is the preferred therapy for hemifacial spasm and can provide transient symptomatic alleviation. Surgical microvascular decompression is a therapeutic approach that targets the underlying cause of this condition and has an average success rate of 85%.
There is no specific antidote for vigabatrin overdose. Standard measures to remove unabsorbed drug should be used, including elimination by emesis or gastric lavage. Supportive measures should be employed, including monitoring of vital signs and observation of the clinical status of the patient.

In an in vitro study, activated charcoal did not significantly adsorb vigabatrin.

The effectiveness of hemodialysis in the treatment of vigabatrin overdose is unknown. In isolated case reports in renal failure patients receiving therapeutic doses of vigabatrin, hemodialysis reduced vigabatrin plasma concentrations by 40% to 60%.
The invention belongs to the field of ethnic medicines and discloses a Yao medicine composition with a function of clearing away heat and toxic materials and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 2-20 parts of Dendrobium aduncum Wall.ex Lindl., 2-20 parts of Tripterospermum affine(Wall.)H.Smith, 2-20 parts of Lonicera japonica Thunb., 2-20 parts of Arctium lappa L. and 1-10 parts of Tinospora sagittata(Oliv.)Gagnep. The dosage form of the composition is powder or tea bags. The preparation method comprises the processes of grinding, baking and sterilizing the raw medicines, thus preparing the powder or tea bags. Clinical tests show that the Yao medicine composition has the functions of clearing away heat and toxic materials, dispelling wind and heat, removing stasis to eliminate swelling, engendering liquid and allaying thirst, clearing away the lung-heat to relieve the sore throat and nourishing yin and cooling blood, and can eliminate inflammation, improve the resistance and achieve the function of clearing away heat and toxic materials. The Yao medicine composition takes effect quickly, has stable curative effects, does not have toxic or side effect and is a health protection medicine with the function of clearing away heat and toxic materials.
Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.